Cargando…

P1293: LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH G-CSF/ATG BASED HAPLOIDENTICAL PROTOCOL PROVIDES FAVORABLE DECREASE IN ACUTE GRAFT-VERSUS-HOST DISEASE FOR SAA PATIENTS

Detalles Bibliográficos
Autores principales:	Xiao-DI, MA, Xu, Zhengli, Han, Tingting, Zhang, Yuan-Yuan, Han, Wei, Fu, Haixia, Zhang, Xiao-Hui, Lin, Fan, Huang, Xiao-Jun, Xu, Lanping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430460/ http://dx.doi.org/10.1097/01.HS9.0000972060.44397.18

Ejemplares similares

Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients
por: Ma, Xiaodi, et al.
Publicado: (2023)

The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia
por: Lin, Fan, et al.
Publicado: (2022)

Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
por: Zhang, Ran, et al.
Publicado: (2022)

P1317: TIME-DEPENDENT ANALYSIS OF THE IMPACT ON EARLY CMV REACTIVATION OF HLA MISMATCH AND ACUTE GRAFT-VERSUS-HOST-DISEASE AFTER ALLO-HSCT FROM RELATED DONORS IN ACQUIRED APLASTIC ANEMIA.
por: Lin, Fan, et al.
Publicado: (2023)

Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia
por: Barkhordar, Maryam, et al.
Publicado: (2022)

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
por: Wang, Yu, et al.
Publicado: (2019)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor
por: Sun, Yu-Qian, et al.
Publicado: (2021)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

1293 Clinical Characteristics of Botulism in the United States, 2002–2012
por: Rao, Agam K., et al.
Publicado: (2014)

Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial
por: Xu, Zhengli, et al.
Publicado: (2023)

Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia
por: Chen, Rong-Long, et al.
Publicado: (2022)

The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide
por: Marwah, Priya, et al.
Publicado: (2019)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study
por: Ma, Yan-Ru, et al.
Publicado: (2021)

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
por: Xuying, Pei, et al.
Publicado: (2023)

Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide
por: Lia, Giuseppe, et al.
Publicado: (2022)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia
por: Wang, Jing-Zhi, et al.
Publicado: (2021)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
por: Patel, Dilan A., et al.
Publicado: (2020)

SAA1 gene variants and childhood obesity in China
por: Zhang, Xiao, et al.
Publicado: (2013)

Rs12218 In SAA1 gene was associated with serum lipid levels
por: Xu, Xiao-Lin, et al.
Publicado: (2013)

Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia
por: Chen, Juan, et al.
Publicado: (2022)

Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets
por: Chang, Ying-Jun, et al.
Publicado: (2015)

Diversity and Complexity of the Mouse Saa1 and Saa2 genes
por: Mori, Masayuki, et al.
Publicado: (2014)

P573: NOVEL PROGNOSTIC MODEL FOR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Wen, Qi, et al.
Publicado: (2023)

Expression of SAA1, SAA2 and SAA4 genes in human primary monocytes and monocyte-derived macrophages
por: Jumeau, Claire, et al.
Publicado: (2019)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases
por: Even-Or, Ehud, et al.
Publicado: (2020)

Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience
por: Zhou, Ling, et al.
Publicado: (2020)

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
por: Nagler, Arnon, et al.
Publicado: (2020)

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood
por: Xu, Xiaoqian, et al.
Publicado: (2020)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
por: Huang, Zhenli, et al.
Publicado: (2022)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA
por: Zu, Yingling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9mmm9ft66bbq230v8va9han0vj